Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$774M |
| 2 |
Intuitive Surgical
ISRG
|
+$654M |
| 3 |
S&P Global
SPGI
|
+$464M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$326M |
| 5 |
CELG
Celgene Corp
CELG
|
+$243M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FedEx
FDX
|
+$591M |
| 2 |
Broadcom
AVGO
|
+$550M |
| 3 |
Monster Beverage
MNST
|
+$408M |
| 4 |
Booking.com
BKNG
|
+$377M |
| 5 |
McDonald's
MCD
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.49% |
| 2 | Consumer Discretionary | 16.46% |
| 3 | Healthcare | 15.81% |
| 4 | Financials | 12.97% |
| 5 | Communication Services | 11.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Moog Inc Class A
MOG.A
$11.9B
| $1.18M | ﹤0.01% |
13,734
-175
| -1% | -$13.8K |
|
|
VNTR
552
DELISTED
Venator Materials PLC
VNTR
| $1.15M | ﹤0.01% |
127,763
-3,037,998
| -96% | -$39.2M |
|
|
CHS
553
DELISTED
Chicos FAS, Inc.
CHS
| $1.15M | ﹤0.01% |
132,492
-27,448
| -17% | -$244K |
|
|
SAFM
554
DELISTED
Sanderson Farms Inc
SAFM
| $1.15M | ﹤0.01% |
11,105
-326
| -3% | -$33.7K |
|
555
Sociedad Química y Minera de Chile
SQM
$22.5B
| $1.09M | ﹤0.01% |
23,778
+232
| +1% | +$10.7K |
|
556
Mueller Water Products
MWA
$3.81B
| $1.03M | ﹤0.01% |
89,132
-71,126
| -44% | -$842K |
|
|
HF
557
DELISTED
HFF Inc.
HF
| $1.02M | ﹤0.01% |
23,936
-7,217
| -23% | -$304K |
|
|
XENT
558
DELISTED
Intersect ENT, Inc
XENT
| $1.01M | ﹤0.01% |
35,260
-1,277,160
| -97% | -$38.4M |
|
|
PMT
559
PennyMac Mortgage Investment
PMT
$814M
| $1.01M | ﹤0.01% |
+50,036
| New | +$983K |
|
560
PagSeguro Digital
PAGS
$2.45B
| $977K | ﹤0.01% |
35,324
+345
| +1% | +$9.38K |
|
561
Globus Medical
GMED
$11.1B
| $947K | ﹤0.01% |
16,682
-217
| -1% | -$11.4K |
|
562
Artisan Partners
APAM
$3.09B
| $946K | ﹤0.01% |
29,194
-368
| -1% | -$12K |
|
|
RVNC
563
DELISTED
Revance Therapeutics, Inc.
RVNC
| $864K | ﹤0.01% |
34,753
-1,097,207
| -97% | -$29.8M |
|
|
CLDT
564
Chatham Lodging
CLDT
$637M
| $849K | ﹤0.01% |
40,624
-514
| -1% | -$11K |
|
565
Accenture
ACN
$116B
| $845K | ﹤0.01% |
4,964
+3,570
| +256% | +$594K |
|
566
Intuit
INTU
$97.9B
| $840K | ﹤0.01% |
3,696
-1,126
| -23% | -$242K |
|
|
RNTX
567
Rein Therapeutics
RNTX
$65.7M
| $835K | ﹤0.01% |
15,185
+120
| +0.8% | +$8.07K |
|
568
Credicorp
BAP
$29.3B
| $829K | ﹤0.01% |
3,718
+36
| +1% | +$8.05K |
|
569
Medpace
MEDP
$16.8B
| $820K | ﹤0.01% |
13,682
-2,431
| -15% | -$133K |
|
570
Acadia Realty Trust
AKR
$2.85B
| $808K | ﹤0.01% |
28,836
-2,737
| -9% | -$75.7K |
|
571
Myriad Genetics
MYGN
$302M
| $803K | ﹤0.01% |
17,457
-11,147
| -39% | -$496K |
|
572
Baidu
BIDU
$32.9B
| $794K | ﹤0.01% |
3,470
-2,662
| -43% | -$626K |
|
|
AMED
573
DELISTED
Amedisys
AMED
| $785K | ﹤0.01% |
6,282
-73
| -1% | -$8.06K |
|
574
Hamilton Lane
HLNE
$4.6B
| $777K | ﹤0.01% |
17,537
-222
| -1% | -$10.7K |
|
|
MRO
575
DELISTED
Marathon Oil Corporation
MRO
| $775K | ﹤0.01% |
33,292
+2,948
| +10% | +$61.7K |
|
Similar funds
Jennison Associates's Q3 2018 Portfolio in Review
As of Q3 2018, Jennison Associates held 739 positions worth $109B, up 5.9% from $103B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jennison Associates's Q3 2018 filing shows 86 new, 214 increased, 352 reduced and 81 closed positions. Its largest new stake was Tiffany & Co.: 1,169,094 shares worth $151M. The largest sale was FedEx, an estimated $591M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Jennison Associates's largest Q3 2018 buy was Tiffany & Co.: 1,169,094 shares worth $151M.
- Jennison Associates added most to AstraZeneca in Q3 2018, an estimated $774M increase.
- Jennison Associates's biggest Q3 2018 reduction was FedEx, cutting an estimated $591M.
- Jennison Associates fully exited Cheniere Energy Partners LP Holdings LLC in Q3 2018, selling an estimated $134M.
- Jennison Associates's ten largest holdings make up 30% of its $109B portfolio in Q3 2018.
- Jennison Associates opened 86 new positions and closed 81 in Q3 2018.
- Jennison Associates's portfolio value rose 5.9% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q3 2018, filed 8 Nov 2018.